“Development of Fixed Dose Combination Products” Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy
The gastrointestinal (GI) tract is one of the most popular and used routes of drug product administration due to the convenience for better patient compliance and reduced costs to the patient compared to other routes. However, its complex nature poses a great challenge for formulation scientists when developing more complex dosage forms such as those combining two or more drugs. Fixed dose combination (FDC) products are two or more single active ingredients combined in a single dosage form. This formulation strategy represents a novel formulation which is as safe and effective compared to every mono-product separately. A complex drug product, to be dosed through a complex route, requires judicious considerations for formulation development. Additionally, it represents a challenge from a regulatory perspective at the time of demonstrating bioequivalence (BE) for generic versions of such drug products. This report gives the reader a summary of a 2-day short course that took place on the third and fourth of November at the Annual Association of Pharmaceutical Scientists (AAPS) meeting in 2018 at Washington, D.C. This manuscript will offer a comprehensive view of the most influential aspects of the GI physiology on the absorption of drugs and current techniques to help understand the fate of orally ingested drug products in the complex environment represented by the GI tract. Through case studies on FDC product development and regulatory issues, this manuscript will provide a great opportunity for readers to explore avenues for successfully developing FDC products and their generic versions.
KEY WORDSbioequivalence fixed dose combination drug products formulation prediction in vivo predictions gastrointestinal physiology
The authors received financial support from the Flemish Research Council (FWO – applicant number: 12R2119N).
Compliance with Ethical Standards
This report represents the scientific views of the authors and not necessarily that of the regulatory authorities presented in this manuscript (U.S. Food and Drug Administration and ANAMED).
- 6.Camilleri M, Malagelada JR, Brown ML, Becker G, Zinsmeister AR. Relation between antral motility and gastric emptying of solids and liquids in humans. American journal of physiology Renal physiology, American journal of physiology Renal physiology [Internet]. 1985 [cited 2017 May 22];249. Available from: https://mayoclinic.pure.elsevier.com/en/publications/relation-between-antral-motility-and-gastric-emptying-of-solids-a.
- 13.Parker HL, Tucker E, Blackshaw E, Hoad CL, Marciani L, Perkins A, et al. Clinical assessment of gastric emptying and sensory function utilizing gamma scintigraphy: establishment of reference intervals for the liquid and solid components of the Nottingham test meal in healthy subjects. Neurogastroenterol Motil. 2017;29.CrossRefGoogle Scholar
- 14.Parker H, Hoad CL, Tucker E, Costigan C, Marciani L, Gowland P, et al. Gastric motor and sensory function in health assessed by magnetic resonance imaging: establishment of reference intervals for the Nottingham test meal in healthy subjects. Neurogastroenterol Motil. 2018;30:e13463.CrossRefGoogle Scholar
- 16.Diaz Tartera HO, Webb D-L, Al-Saffar AK, Halim MA, Lindberg G, Sangfelt P, et al. Validation of SmartPill® wireless motility capsule for gastrointestinal transit time: intra-subject variability, software accuracy and comparison with video capsule endoscopy. Neurogastroenterol Motil. 2017;29:1–9.CrossRefGoogle Scholar
- 17.Heissam K, Abrehart N, Hoad CL, Wright J, Menys A, Murray K, et al. Measuring fasted state gastric motility before and after a standard BA/BE 8 oz drink of water: validation of new MRI imaging protocols against concomitant perfused manometry in healthy participants. Annual AAPS Meeting. Washington, DC, November 4-7 2018.Google Scholar
- 18.Hoad C, Clarke C, Marciani L, Graves MJ, Corsetti M. Will MRI of gastrointestinal function parallel the clinical success of cine cardiac MRI? BJR. 2018;92:20180433.Google Scholar
- 27.Corsetti M, Costa M, Bassotti G, Bharucha AE, Borrelli O, Dinning PG. First “translational” consensus on terminology and definition of colonic motility as studied in humans and animals by means of manometric and non-manometric techniques. Nat Rev. in press.Google Scholar
- 28.Mark EB, Poulsen JL, Haase A-M, Espersen M, Gregersen T, Schlageter V, et al. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system. Neurogastroenterology & Motility. 2019;31:e13451.Google Scholar
- 51.Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, et al. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci. 2014;57:99–151.CrossRefGoogle Scholar
- 55.Carmona-Ibáñez G, del Bermejo-Sanz MV, Rius-Alarcó F, Martin-Villodre A. Experimental studies on the influence of surfactants on intestinal absorption of drugs cefadroxil as model drug and sodium taurocholate as natural model surfactant: studies in rat colon and in rat duodenum. Arzneimittelforschung. 1999;49:44–50.PubMedGoogle Scholar
- 58.Guillaume P, Provost D, Lacroix P. Gastrointestinal models: intestinal transit, gastric emptying, and ulcerogenic activity in the rat. Curr Protoc Pharmacol. 2008;Chapter 5:Unit5.3.Google Scholar
- 63.Colón-Useche S, González-Álvarez I, Mangas-Sanjuan V, González-Álvarez M, Pastoriza P, Molina-Martínez I, et al. Investigating the discriminatory power of BCS-biowaiver in vitro methodology to detect bioavailability differences between immediate release products containing a class I drug. Mol Pharm. 2015;12:3167–74.CrossRefGoogle Scholar
- 64.World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organ Tech Rep Ser. 2005;929:1–142 backcover.Google Scholar
- 65.US Food & Drug Administration. Guidance for industry on fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV; availability [Internet]. Federal Register. 2006 [cited 2019 Jan 15]. Available from: https://www.federalregister.gov/documents/2006/10/18/E6-17324/guidance-for-industry-on-fixed-dose-combinations-co-packaged-drug-products-and-single-entity.
- 66.European Medicines Agency. Guideline on clinical development of fixed combination medicinal products. 2017;12. Last accessed on March 6, 2019.Google Scholar
- 67.When to Submit an ANDA vs. a 505(b)(2) Application: FDA Discusses in Draft Guidance [Internet]. [cited 2019 Jan 15]. Available from: https://www.raps.org/regulatory-focus™/news-articles/2017/10/when-to-submit-an-anda-vs-a-505(b)(2)-application-fda-discusses-in-draft-guidance.
- 69.Kohlrausch A. Bilayer tablet of telmisartan and simvastatin [Internet]. 2006 [cited 2019 Jan 15]. Available from: https://patents.google.com/patent/US20060078615A1/en.
- 71.Food & Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system guidance for industry [Internet]. 2015 [cited 2017 Jan 17]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf.
- 72.European Medicines Agency. Guideline on the investigation of bioequivalence [Internet]. 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
- 73.Canada H, Canada H. Guidance document: biopharmaceutics classification system based biowaiver [Internet]. aem. 2014 [cited 2019 Jan 15]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/biopharmaceutics-classification-system-based-biowaiver.html.
- 74.US Food & Drug Administration. In vitro metabolism- and transporter-mediated drug-drug interaction studies, and clinical drug interaction studies-study design, data analysis, and clinical implications; draft guidances for industry; availability [Internet]. Federal Register. 2017 [cited 2019 Jan 15]. Available from: https://www.federalregister.gov/documents/2017/10/25/2017-23102/in-vitro-metabolism%2D%2Dand-transporter-mediated-drug-drug-interaction-studies-and-clinical-drug.
- 75.European Medicines Agency. European Medicines Agency updates guideline on drug interactions [Internet]. 2012 [cited 2019 Jan 15]. Available from: https://www.ema.europa.eu/en/news/european-medicines-agency-updates-guideline-drug-interactions.
- 83.Dey S, Chattopadhyay S, Mazumder B. Formulation and Evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release. Biomed Res Int [Internet]. 2014 [cited 2019 Apr 25];2014. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909979/.
- 87.Guia para Registro de Novas Associações em Dose Fixa - Busca - Anvisa [Internet]. [cited 2019 Jan 15]. Available from: http://portal.anvisa.gov.br/resultado-de-busca?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-1&p_p_col_count=1&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=352621&_101_type=document.
- 92.US Food & Drug Administration. Guidance, compliance, & regulatory information [Internet]. [cited 2019 Mar 5]. Available from: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/default.htm.